{
    "clinical_study": {
        "@rank": "161262", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Other", 
                "description": "Epoetin alfa Test drug in the first period and comparator drug in the second period."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Other", 
                "description": "Epoetin alfa Comparator Drug in the first period and test drug in the second period"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this trial is that the test drug (Eritromax \u00ae) pharmacokinetics and\n      pharmacodynamics parameters are similar to the comparator drug (Eprex \u00ae) in healthy subjects\n      following administration of single intravenous dose. The objective of this randomized,\n      crossover, clinical trial is to evaluate the pharmacokinetic and pharmacodynamic profile of\n      the drug Eritromax\u00ae marketed by Blau Farmac\u00eautica, compared to the product Eprex \u00ae, produced\n      by Janssen-Cilag, by assessing plasma concentration of the drug and the reticulocyte count\n      following a single-dose intravenous administration of 100 IU/kg in healthy subjects."
        }, 
        "brief_title": "PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agree to all the purposes of the study by signing and dating the Informed Consent;\n\n          -  Male, aged between 20 and 55 years, clinically healthy;\n\n          -  BMI between 18.5 and 30;\n\n          -  Hemoglobin between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;\n\n          -  VCM between 82 and 98, HBMC between 26 and 34, platelets between 150,000 and 400,000\n             units per mL. and WBC between 3,500 to 10,500 units per ml and no atypical cells.\n\n          -  Human serum ferritin between 36-262 mcg / L;\n\n          -  Counting of reticulocytes in peripheral blood \u2264 3%;\n\n          -  Serum erythropoietin < 30 mIU / mL.\n\n        Exclusion Criteria:\n\n          -  Participation in clinical trials in the 12 months preceding the survey;\n\n          -  Body weight > 100 kg;\n\n          -  Presence of iron deficiency anemia;\n\n          -  Presence of pulmonary, cardiovascular, neurological, endocrine, gastrointestinal,\n             genitourinary or other systems diseases;\n\n          -  Acute disease in the period of 07 days before the beginning of the practical phase\n             (administration of the drug) of the study;\n\n          -  Chronic administration of medications for hypertension, diabetes or any other disease\n             that requires continuous use of any drug;\n\n          -  Hormone therapy in the period of 02 months preceding the beginning of the practical\n             phase (administration of the drug) of the study;\n\n          -  Administration of any drug in the 02 weeks prior to the start of the practical period\n             of the study;\n\n          -  Clinical history of autoimmune or hereditary anemia;\n\n          -  Clinical history of chronic bleeding;\n\n          -  Clinical history of acute bleeding in the 30 days preceding the beginning of\n             practical phase of the study (administration of the drug);\n\n          -  Clinical history of allergy of biological products derived from mammalian albumin or\n             any component of the formulation;\n\n          -  Current or previous history (less than 12 months) of illicit drug abuse and / or\n             tobacco and / or alcohol or having consumed alcohol within 48 hours prior to the\n             practical study periods (administration of the drug);\n\n          -  Prior therapies with erythropoietin;\n\n          -  Albumin below 3.5 g/dL or higher than 4.8 g/dL;\n\n          -  Signs or clinical history of bone marrow aplasia;\n\n          -  History and clinical or laboratory liver disease;\n\n          -  History and clinical or laboratory nephropathy;\n\n          -  Principal Investigator of the study criteria."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664195", 
            "org_study_id": "EPOBLA0312IV-I", 
            "secondary_id": "Version 1 01/03/2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "description": "Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.", 
            "intervention_name": "Epoetin Alfa", 
            "intervention_type": "Drug", 
            "other_name": [
                "Eritromax", 
                "Eprex"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "subjects", 
        "lastchanged_date": "August 10, 2012", 
        "location": {
            "contact": {
                "email": "bruna.franco@lalclinica.com.br", 
                "last_name": "Bruna Franco", 
                "phone": "+55 19 38716399"
            }, 
            "contact_backup": {
                "email": "nath\u00e1lia.ribeiro@lalclinica.com.br", 
                "last_name": "Nath\u00e1lia Ribeiro", 
                "phone": "+55 19 38716399"
            }, 
            "facility": {
                "address": {
                    "city": "Valinhos", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13276-245"
                }, 
                "name": "LAL Cl\u00ednica"
            }, 
            "investigator": {
                "last_name": "Alexandre Frederico", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmac\u00eautica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Study.", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico", 
            "phone": "+55 11 38716399"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Time frame on days 1, 8, 19 and 22: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h and 12h after administration;\nTime frame on day 26: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 36h after last drug administration.", 
                "measure": "rHuEPO serum concentration", 
                "safety_issue": "Yes", 
                "time_frame": "0, 10, 20, 30, 40, 50 minutes 1, 2, 4, 6, 8, 10, 12, 24, 36 e 48 hours after drug administration"
            }, 
            {
                "description": "Time frame on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26: 10 minutes before drug administration.\nTime frame on day 29: 72 hours +/- 2 hours after last drug administration.", 
                "measure": "plasma reticulocyte count", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 and 29 days after first administration of the drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664195"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}